|
|
 |
|
Viewing report
|
|
|
|
Global Biopharma Outlook 2012 - Major US and EU Pharma
MP Advisors, Jan 2012, Pages: 109
Global Biopharma Outlook 2012 –Major US and EU Pharma
Unarguably 2011 was one of the very good years for the global Pharma industry as the USFDA approved a trend setting 39 new drugs, which is way ahead of the 20-25 approvals observed over the last so many years. In 2012 although patent expiries will pose pressure on growth, but innovation will continue to deliver. 2012 should emerge as strong as 2011 in terms of new approvals.
A very strong positive news-flow on late stage pipeline products in select therapy areas - Melanoma, HCV, Anticoagulants, Alzheimers, Multiple Sclerosis, diabetes-GLP-1 should set-in a new growth trend. The oncology space, driven by innovation around personalized therapy will undergo major evolution over the next few years. To dissuade the biosimilar threat, the larger cap biologic companies are actively focusing on life cycle management, and is likely to pose threat for small companies investing in biosimilars in lure of new growth.
The margin improvement initiatives through cost containment, restructuring, additional share repurchase program, and dividend policy is still encouraging for the Investor to continue to remain invested in the large cap stocks, by the time one can see new growth driven by innovation and emerging markets taking these companies to a new level.
Global Biopharma Outlook 2012-Major US and EU Pharma, released by MP Advisors provides a complete analyses of individual large cap companies, their PhII and PhIII pipeline, important therapy areas where new innovation will create new leaders, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.
This report is also intended for the generic pharmaceutical companies, and small to mid cap research focused companies as it will help them identify product opportunities and potential partners.
Company Analyses:
AstraZeneca
Bristol Myers-Squibb
Pfizer
Merck
Novartis
Novo Nordisk
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
|
|
|
|
